GenomeKey
PrivateLast Round
Grant
Jul 31, 2024
Total Funding Raised
$12.86M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
GenomeKey is a healthcare technology company that develops a rapid diagnostic platform intended to identify bacteria and determine antimicrobial resistance.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Medical AI, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts, Hardware + Subscription, Usage-Based SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GenomeKey Comparables
Compare GenomeKey with similar companies based on industry and business-model similarity.
GenomeKey Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 31, 2024 | ||||
| Grant | May 23, 2022 | ||||
| Grant | Apr 27, 2021 | ||||
| Seed | Jan 12, 2021 |
Key People
Founding team and executive leadership
GenomeKey Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CARB-X | Grant |
| Bristol Private Equity Club | Seed |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors grew 133% MoM, reaching 3.2K.
- Jul 13, 2026
Open roles increased to 25, representing 71% of headcount.
GenomeKey Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GenomeKey's valuation, stock price, and market status.
Is GenomeKey a public or private company?
GenomeKey is a private company.
What is the current stock price of GenomeKey?
GenomeKey is a private company, so its shares have no public market price. Caplight tracks GenomeKey's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GenomeKey worth (valuation)?
Valuation information for GenomeKey is not publicly available.
Can I buy GenomeKey stock?
GenomeKey shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GenomeKey's last funding round?
GenomeKey's most recent funding round was Grant on July 31, 2024.
Who are the main investors in GenomeKey?
Key investors in GenomeKey include CARB-X, Bristol Private Equity Club, Innovate UK.
Will GenomeKey IPO soon?
No public IPO plans have been announced for GenomeKey.
How can I track GenomeKey secondary market activity?
Caplight tracks bids, offers, and trades in GenomeKey's shares on secondary markets.